{
    "clinical_study": {
        "@rank": "35259", 
        "acronym": "JPMS-CRVO", 
        "arm_group": {
            "arm_group_label": "Group 1", 
            "description": "Eylea treatment goup"
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, non-interventional, multi center post-authorization safety study that\n      includes patients with a diagnosis of CRVO.  The investigator will have made the choice of\n      treatment (EYLEA) as well as the decision to use EYLEA according the Japanese Package Insert\n      prior to enrolling the patient in this study.\n\n      The observation period for each patient starts when therapy with EYLEA is initiated. The\n      enrollment period is 2 years. Patients will be followed for a time period of 2 years or\n      until it is no longer possible (e.g. lost to follow-up) within the 2 years.\n\n      For each patient, data are collected as defined in the case report form at the initial\n      visit, follow-up visits and final visit, either by routine clinical visits (as per\n      investigators routine practice).\n\n      There will interim analysis of study data: 6 months after last patient first visit and\n      J-PSUR(Japanese-Periodic Safety Update Report )"
        }, 
        "brief_title": "Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)", 
        "completion_date": {
            "#text": "September 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Retinal Vein Occlusion", 
        "condition_browse": {
            "mesh_term": "Retinal Vein Occlusion"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who start EYLEA treatment for CRVO\n\n        Exclusion Criteria:\n\n          -  Patients who have already received EYLEA treatment\n\n          -  Patients who are contraindicated based on approved label"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Female and male patients with a diagnosis of CRVO will be enrolled after the decision for\n        treatment with EYLEA has been made by the investigator. Those patients prescribed EYLEA\n        previously will not be included in this study. Physicians should consult the full\n        prescribing information for EYLEA before enrolling patients and familiarize themselves\n        with the safety information in the product package label. Eligible patients who receive\n        EYLEA will be enrolled and documented in the eCRF."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040220", 
            "org_study_id": "16641", 
            "secondary_id": "EYL-CRVO"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "2 mg of Eylea will be treated per one injection at more than one months interval usually.", 
            "intervention_name": "Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "CRVO, Macular edema, Aflibercept, anti-VEGF", 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Special Drug Use Investigation of EYLEA for CRVO", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency, Ministry of Health, Labour and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of episodes of adverse drug reactions and adverse events(serious or non-serious, related or not related, ocular or non ocular)", 
            "safety_issue": "Yes", 
            "time_frame": "6 months after start of treatment with the drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040220"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Effectiveness (visual acuity)", 
                "safety_issue": "No", 
                "time_frame": "6months after start of treatment with the drug"
            }, 
            {
                "measure": "Effectiveness (retina thickness)", 
                "safety_issue": "No", 
                "time_frame": "6months after start of treatment with the drug"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}